This makes Ozempic the first GLP-1 receptor agonist approved for kidney ... with established players like Novo Nordisk, Eli ...

There is multidistrict litigation, or an MDL, in progress against pharmaceutical companies Novo Nordisk and Eli Lilly and Co.

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.  Claims of ...